Download PDF
Thorac Cardiovasc Surg
DOI: 10.1055/s-0043-1769099
Original Cardiovascular

Transapical Transcatheter Mitral Valve Implantation with the Tendyne Valve: The Swiss Experience

Maria Nucera    *
1   Department of Cardiac Surgery, Cardiovascular Center, Inselspital University Hospital Bern, Bern, Switzerland
,
Jules Miazza   *
2   Department of Cardiac Surgery, Universitätsspital Basel, Basel, BS, Switzerland
,
Fabien Praz
3   Department of Cardiology, Inselspital University Hospital Bern, Bern, Switzerland
,
Christoph Kaiser
4   Department of Cardiology, Universitätsspital Basel, Basel, BS, Switzerland
,
Matthias Siepe
1   Department of Cardiac Surgery, Cardiovascular Center, Inselspital University Hospital Bern, Bern, Switzerland
,
David Reineke   **
1   Department of Cardiac Surgery, Cardiovascular Center, Inselspital University Hospital Bern, Bern, Switzerland
,
Oliver Reuthebuch    **
2   Department of Cardiac Surgery, Universitätsspital Basel, Basel, BS, Switzerland
› Author Affiliations Funding None.
› Further Information
    Permissions and Reprints All articles of this category

Abstract

Background The aim of this study was to report outcomes of all patients undergoing transcatheter mitral valve implantation with the Tendyne Mitral Valve System (Tendyne) in Switzerland.

Methods We retrospectively analyzed preoperative echocardiographic and computed tomography (CT) data, procedural findings, and 30-day and 1-year follow-up echocardiographic and clinical data of patients who underwent transcatheter mitral valve implantation with Tendyne in Switzerland.

Results A total of 24 patients (age, 74.8 ± 7.8 years; 67% male) underwent transapical transcatheter mitral valve implantation with Tendyne between June 2020 and October 2022. Technical success rate was 96%. In five patients, concomitant interventions in the form of transcatheter aortic valve implantation (one patient), minimally invasive direct coronary artery bypass (one patient), and transcatheter edge-to-edge repair (three patients) were performed prior to or after the index procedure. There was one device embolization, and two patients required valve retrieval. In-hospital outcomes included one stroke and three major bleeding events. None of the patients died within 30 days. Two patients were rehospitalized for decompensated heart failure. At 1-year follow-up, there were three noncardiovascular-related deaths.

Conclusion Transcatheter mitral valve implantation with Tendyne is feasible to treat polymorbid patients suffering from complex mitral valve disease as well as patients with previous mitral interventions. Perioperative risk was acceptable and procedural success high.

Keywords

mitral valve - mitral valve disease - transcatheter mitral valve replacement

Authors' Contribution

The study was undertaken in equal parts in Bern and Basel. David Reineke and Oliver Reuthebuch have selected the patients, done the procedures, and are therefore in equal parts at the origin of this work. They have initiated the publication of the data and designed its outlines. They have treated the patients, collected their consent and done the in-house follow-up, designed the paper, and edited the article with focus on the patients at their centers.


The same applies for the first authors, who had corresponding roles at their centers, doing follow-up for their patients, getting the ethic committees approval for their respective patients, and writing the document. The same applied for the review.


The only thing that was done exclusively in one center is the filming of the procedure.


Data Availability Statement

Raw data were generated at University Hospital Bern and at University Hospital Basel. All relevant data are within the manuscript.


* These authors contributed equally to this manuscript and are joint first authors.


** These authors contributed equally to this manuscript and are joint last authors.




Publication History

Received: 17 November 2022

Accepted: 13 April 2023

Article published online:
16 June 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Coffey S, Cairns BJ, Iung B. The modern epidemiology of heart valve disease. Heart 2016; 102 (01) 75-85
    CrossrefPubMedGoogle Scholar
  • 2 Iung B, Baron G, Butchart EG. et al. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003; 24 (13) 1231-1243
    CrossrefPubMedGoogle Scholar
  • 3 Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet 2006; 368 (9540): 1005-1011
    CrossrefPubMedGoogle Scholar
  • 4 Mirabel M, Iung B, Baron G. et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery?. Eur Heart J 2007; 28 (11) 1358-1365
    CrossrefPubMedGoogle Scholar
  • 5 Goel SS, Bajaj N, Aggarwal B. et al. Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure: comprehensive analysis to determine the potential role of MitraClip for this unmet need. J Am Coll Cardiol 2014; 63 (02) 185-186
    CrossrefPubMedGoogle Scholar
  • 6 Vahanian A, Beyersdorf F, Praz F. et al; ESC/EACTS Scientific Document Group. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur J Cardiothorac Surg 2021; 60 (04) 727-800
    CrossrefPubMedGoogle Scholar
  • 7 Sticchi A, Reineke D, Praz F, Windecker S. Transcatheter mitral valve replacement for mitral valve-in-valve, valve-in-ring, and valve-in-MAC using balloon-expandable transcatheter heart valves. JACC Cardiovasc Interv 2021; 14 (08) 873-878
    CrossrefPubMedGoogle Scholar
  • 8 Stone GW, Adams DH, Abraham WT. et al; Mitral Valve Academic Research Consortium (MVARC). Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: Part 2: endpoint definitions: a consensus document from the Mitral Valve Academic Research Consortium. J Am Coll Cardiol 2015; 66 (03) 308-321
    CrossrefPubMedGoogle Scholar
  • 9 Mehran R, Rao SV, Bhatt DL. et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123 (23) 2736-2747
    CrossrefPubMedGoogle Scholar
  • 10 Bartkowiak J, Reineke D, Tomii D. et al. Electrosurgical laceration and stabilization of MitraClip followed by valve implantation for iatrogenic mitral stenosis. JACC Cardiovasc Interv 2022; 15 (01) 110-112
    CrossrefPubMedGoogle Scholar
  • 11 Miazza J, Koechlin L, Jeger RV, Reuthebuch OT. First-in-man concomitant mitral valve replacement and coronary artery bypass grafting using a single minimally invasive access. Eur J Cardiothorac Surg 2022; 62 (01) ezac330
    CrossrefPubMedGoogle Scholar
  • 12 Reineke D, Brugger N, Wild MG. et al. Hemolysis after transcatheter mitral valve implantation resolved by valve retensioning. JACC Case Rep 2021; 3 (06) 864-870
    CrossrefPubMedGoogle Scholar
  • 13 Muller DWM, Farivar RS, Jansz P. et al; Tendyne Global Feasibility Trial Investigators. Transcatheter mitral valve replacement for patients with symptomatic mitral regurgitation: a global feasibility trial. J Am Coll Cardiol 2017; 69 (04) 381-391 [published correction appears in J Am Coll Cardiol. 2017 Mar 7;69(9):1213]
    CrossrefPubMedGoogle Scholar
  • 14 Kargoli F, Pagnesi M, Rahgozar K. et al. Current devices and complications related to transcatheter mitral valve replacement: the bumpy road to the top. Front Cardiovasc Med 2021; 8: 639058
    CrossrefPubMedGoogle Scholar
  • 15 Grinberg D, Pozzi M, Bernard C, Obadia JF. A tensed Tendyne. Eur J Cardiothorac Surg 2020; 58 (03) 651-653
    CrossrefPubMedGoogle Scholar